Richard Jacinto II bought $1.4M of DMAC
owner at DiaMedica Therapeutics Inc.. 400,000 shares at an average of $3.50, traded Jul 23, 2025, filed Jul 25, 2025.
Score components
- +12Role10% owner
- +25Trade size$1.4M at market
- +3Relative to holdingsHoldings up 9%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.0%, 3m +36.2%, 6m +68.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-023532, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 23, 2025 | POpen-market purchase Voting Common Shares, no par value per shareindirect: By Roth IRA | +400,000 | $3.50 | $1.4M | 4,958,823 | Jul 25, 2025 |
Related signals
Other insiders at DiaMedica Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $7.6M 1,061,277 shares | +14% | |
| 40Moderate | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $6.0M 1,000,000 shares | +15% | |
| 57Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $10.0M 2,857,142 shares | +52% | |
| 53Moderate | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $5.4M 1,542,857 shares | +30% | |
| 30Weak | DMACbuy DiaMedica Therapeutics Inc. | David J. Wambeke Chief Business Officer | $49k 20,000 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.